Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children treated with roflumilast cream 0.05% achieved a 75% improvement in Eczema Area and Severity Index (EASI-75), a key secondary endpointNew data highlight rapid and significant reduction in itch as early as 24 hours following first application of roflumilast cream 0.05% based on daily Worst Itch Numeric Scale (WI-NRS ...

Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signatureSuggests skin barrier disruption in seborrheic dermatitis is distinct with its own disease-specific pattern SAN DIEGO, Calif., March 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, highlights new research that, for the first time, reveals the gene expression pro ...

Company Overview - Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on immuno-dermatology, addressing the needs of individuals with immune-mediated dermatological diseases [5] - The company has a growing portfolio that includes two FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [5] Recent Offering - Arcutis announced the closing of its underwritten public offering of 18,157,895 shares of common stock at a price of $9.50 per share, resulting in total gross proceeds of approximately $172.5 million before deductions [1] - The offering included 2,368,421 shares issued upon the exercise of the underwriters' option to purchase additional shares [1] - Morgan Stanley, TD Cowen, and Guggenheim Securities acted as joint lead bookrunning managers for the offering, with Mizuho and Needham & Company serving as co-lead managers [2] Regulatory Compliance - The shares were offered pursuant to an effective shelf registration statement on Form S-3 filed with the SEC on January 31, 2024, with a final prospectus supplement available on the SEC's website [3]

Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $10.28, gaining 54.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $16.33 indicates a 58.9% upside potential.The average comprises six short-term price targets ranging from a low of $6 to a high of $38, with a standard deviation of $12.09. While the lowest estimate indicates a decline of 41.6% from the curre ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arcutis Biotherapeutics, Inc. (ARQT) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Arcutis Biotherapeutics, Inc. is a member of our Medical group, which includes 1067 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector ...

Core Insights - Arcutis Biotherapeutics, Inc. is participating in the TD Cowen 44th Annual Health Care Conference on March 4, 2024, at 2:10 pm ET [1] - The company focuses on developing innovations in immuno-dermatology and has a growing portfolio that includes two FDA-approved products [2] Company Overview - Arcutis is a commercial-stage medical dermatology company addressing immune-mediated dermatological diseases [2] - The company has a robust pipeline with multiple clinical programs targeting inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [2]

Core Insights - Arcutis Biotherapeutics, Inc. is participating in the TD Cowen 44th Annual Health Care Conference on March 4, 2024, at 2:10 pm ET [1] - The company focuses on developing innovations in immuno-dermatology and has a growing portfolio that includes two FDA-approved products [2] Company Overview - Arcutis is a commercial-stage medical dermatology company addressing immune-mediated dermatological diseases [2] - The company has a robust pipeline with multiple clinical programs targeting inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [2]

Core Viewpoint - Arcutis Biotherapeutics, Inc. has announced a public offering of common stock, pricing at $9.50 per share, aiming to raise approximately $150 million to support its dermatology programs and general corporate purposes [1][2]. Group 1: Offering Details - Arcutis is offering 15,789,474 shares of common stock, with an additional option for underwriters to purchase up to 2,368,421 shares within 30 days [1]. - The offering is expected to close on March 4, 2024, pending customary conditions [1]. - The offering is made under an effective shelf registration statement filed with the SEC on January 31, 2024 [3]. Group 2: Use of Proceeds - The net proceeds will be utilized for the commercialization, development, and approval of programs targeting atopic dermatitis and scalp psoriasis, as well as for working capital and other corporate purposes [2]. Group 3: Company Overview - Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on immuno-dermatology, with a portfolio that includes two FDA-approved products [5]. - The company aims to address the needs of patients with immune-mediated dermatological diseases through innovative therapies [5]. - Arcutis has a robust pipeline with multiple clinical programs for inflammatory dermatological conditions, including psoriasis and atopic dermatitis [5].

Company Overview - Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on immuno-dermatology innovations [5] - The company has a growing portfolio that includes two FDA-approved products and a robust pipeline targeting inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [5] Public Offering Announcement - Arcutis announced a public offering of $150 million in common stock and pre-funded warrants, with an additional 30-day option for underwriters to purchase up to $22.5 million more [1][2] - The offering is subject to market conditions and there is no assurance regarding its completion or terms [1] Underwriters and Registration - Morgan Stanley, TD Cowen, and Guggenheim Securities are the joint lead bookrunning managers for the offering, with Mizuho and Needham & Company as co-lead managers [2] - The securities are being offered under an effective shelf registration statement filed with the SEC on January 31, 2024 [2]

Core Insights - Arcutis Biotherapeutics has entered a strategic collaboration with Sato Pharmaceutical for the development and commercialization of topical roflumilast in Japan, which includes a $25 million upfront payment and potential milestone payments totaling $40 million [1][3] - The partnership aims to provide a novel non-steroidal treatment option for millions of Japanese patients suffering from inflammatory skin diseases [1][2] Financial Terms - Arcutis will receive an upfront payment of $25 million and may earn an additional $40 million based on achieving specific regulatory and sales milestones [3] - The company is also eligible for tiered, low double-digit percentage royalties from the sales of the product in Japan [3] Product Information - Topical roflumilast is a next-generation phosphodiesterase type 4 (PDE4) inhibitor, indicated for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis [1][4] - The product is being developed in cream and foam formulations, which are designed to be effective and well-tolerated for patients [2][4] Company Background - Arcutis Biotherapeutics focuses on innovations in immuno-dermatology and has a growing portfolio that includes FDA-approved products targeting immune-mediated dermatological diseases [8] - Sato Pharmaceutical is committed to healthcare innovation and provides high-quality products, particularly in dermatology [9]